SEC Tracker
Get the app

Faeth Therapeutics FTH

Faeth Therapeutics adds new director

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Board increased to seven members
  2. Adam Schayowitz appointed as Class III director
  3. Received 25,000 stock options
  4. No family ties or conflicts disclosed

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Faeth Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zeo ScientifiX ZEOX public float $7M, Apr 30, 2025, over 18 months old
  2. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  3. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  4. CV Sciences CVSI public float $7M, Jun 30, 2025
  5. Minerva Neurosciences NERV public float $7M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.